Results 21 to 30 of about 9,194 (267)

Alpha emitter radium-223 in patients with metastatic castration-resistant prostate cancer: A cost-utility analysis

Frontiers in Pharmacology, 2022
Objective: To assess the cost effectiveness of radium-223 dichloride for patients with metastatic castration-resistant prostate cancer (mCRPC) in China.Materials and methods: A Markov model was developed to estimate the long-term health and economic ...
Xiaohui Zeng, Qiao Liu, Chongqing Tan, Xiaomin Wan, Yunhua Wang, Xiaowei Ma   +5 more
doaj   +1 more source

Histopathology of castration-resistant prostate cancer confirms changes in bone metastasis during radium-223 treatment: A case report

Urology Case Reports, 2020
Radium-223 is used for treating castration-resistant prostate cancer with bone metastases. Here, we report the case of a 76-year-old man diagnosed with castration-resistant prostate cancer with bone metastases who was started on radium-223.
Masato Dobashi, Dai Kouguchi, Yukiko Kanetsuna, Junichiro Ishii   +3 more
doaj   +1 more source

Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer [PDF]

, 2017
is the first targeted alpha therapy for patients with castration resistant prostate cancer and symptomatic bone metastases. Radium-223 provides a new treatment option for this setting, but also necessitates a new treatment management approach.
Carrió, Ignasi, De Vincentis, Giuseppe, Du, Yong, Fanti, Stefano, Ilhan, Harun, Lewington, Val, Mommsen, Caroline, Nitzsche, Egbert, Oyen, Wim, Sundram, Francis, Universitat Autònoma de Barcelona, Vogel, Wouter   +11 more
core   +4 more sources

Hematologic Toxicity of Concurrent Administration of Radium-223 and Next-generation Antiandrogen Therapies. [PDF]

, 2017
PURPOSE/OBJECTIVES: Radium-223 is a first-in-class radiopharmaceutical recently approved for the treatment of castration-resistant prostate cancer in patients with symptomatic bone metastases.
Basch, Beer, Chen, Cookson, De Bono, Den, Dreicer, Fizazi, Hoskin, Kantoff, Keizman, Morris, Nilsson, Nilsson, Parker, Petrylak, Ryan, Scher, Siegel, Tannock, Tu   +20 more
core   +2 more sources

Chemotherapy following radium-223 dichloride treatment in ALSYMPCA [PDF]

, 2016
BACKGROUND Radium-223 prolongs overall survival in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases, regardless of prior docetaxel.
Coleman, R.E., Hoskin, P., Nilsson, S., Parker, C., Petrenciuc, O., Sartor, O., Staudacher, K., Thuresson, M., Vogelzang, N.J.   +8 more
core   +2 more sources

PCN74 Cost-Effectiveness of Radium-223 Dichloride (Radium-223) In Alsympca: A Cost-Effectiveness Analysis of Radium-223+Best Standard of Care (Bsoc) Compared With Placebo+Bsoc In Treatment of Castration-Resistant Prostate Cancer (Crpc) And Symptomatic Bone Metastases In Canada [PDF]

, 2015
Current models of sexual functioning imply an important role for both automatic and controlled appraisals. Accordingly, it can be hypothesized that erectile dysfunction may be due to the automatic activation of negative appraisals at the prospect of ...
Henricks, P., Cislo, P., Zhan, L., Beaudet, A., Grabbi, E., Lloyd, A., Fleshner, N., Chin, W.   +7 more
core   +5 more sources

Optimal usage of radium-223 in metastatic castration-resistant prostate cancer

Journal of the Formosan Medical Association, 2017
Radium-223 is a first-in-class α-emitting radiopharmaceutical that targets bone metastases associated with metastatic castration-resistant prostate cancer (mCRPC).
Tai-Lung Cha, Tony Tong-Lin Wu, Nicholas John Vogelzang, Chao-Yuan Huang, Shu-Pin Huang, Chia-Chi Lin, Yen-Chuan Ou, See-Tong Pang, Daniel Heung-Yuan Shen, Wen-Jeng Wu, Wayne Yen-Hwa Chang   +10 more
doaj   +1 more source

Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study [PDF]

, 2016
Background: Radium-223 dichloride (radium-223), a first-in-class α-emitting radiopharmaceutical, is recommended in both pre- and post-docetaxel settings in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases based on
Agresti, Basch, Basch, Berruti, Bottomley, Cella, Cella, Cella, Cella, Cherny, Chow, Cislo, Esper, Fitzpatrick, Harland, Hedeker, Hoskin, Jones, Neter, Nilsson, Nilsson, Nilsson, Parker, Parker, Pickard, Quinten, Sartor, Sternberg, Sullivan, Sullivan, Victorson, Weinfurt, Yost   +32 more
core   +2 more sources

Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice [PDF]

, 2019
Purpose: REASSURE is a global, prospective, non-interventional study to assess long-term safety of radium-223 in patients with bone metastatic castration-resistant prostate cancer.
Bayh I., Bourre J.-C., Dizdarevic S., Du Y., Essler M., Ezziddin S., Kalinovsky J., la Fougere C., Paganelli G., Petersen P.M., Valdagni R., Versari A.   +11 more
core   +1 more source

Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.

PLoS ONE, 2019
BackgroundRadium-223 is a targeted alpha-particle therapy that improves survival in men with metastatic castration resistant prostate cancer (mCRPC), particularly in men with elevated serum levels of bone alkaline phosphatase (B-ALP).
Andrew J Armstrong, Santosh Gupta, Patrick Healy, Gabor Kemeny, Beth Leith, Michael R Zalutsky, Charles Spritzer, Catrin Davies, Colin Rothwell, Kathryn Ware, Jason A Somarelli, Kris Wood, Thomas Ribar, Paraskevi Giannakakou, Jiaren Zhang, Drew Gerber, Monika Anand, Wen-Chi Foo, Susan Halabi, Simon G Gregory, Daniel J George   +20 more
doaj   +1 more source